BioNano Genomics Inc (NASDAQ:BNGO) has received an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $11.50 for the company and are anticipating that the company will post ($0.57) EPS for the current quarter, according to Zacks. Zacks has also assigned BioNano Genomics an industry rank of 69 out of 256 based on the ratings given to related companies.
Several brokerages have issued reports on BNGO. Zacks Investment Research upgraded shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research note on Monday, July 8th. Maxim Group reiterated a “buy” rating and issued a $12.00 price target on shares of Intec Pharma in a research note on Thursday, June 20th.
Shares of NASDAQ:BNGO traded up $0.01 during midday trading on Thursday, reaching $2.53. 1,804 shares of the company were exchanged, compared to its average volume of 16,492. BioNano Genomics has a fifty-two week low of $2.35 and a fifty-two week high of $10.00. The company has a debt-to-equity ratio of 3.13, a quick ratio of 5.64 and a current ratio of 5.94. The stock’s fifty day moving average price is $2.70. The firm has a market cap of $27.34 million and a price-to-earnings ratio of -0.97.
BioNano Genomics (NASDAQ:BNGO) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.12). The business had revenue of $1.85 million for the quarter, compared to analysts’ expectations of $1.76 million. As a group, analysts expect that BioNano Genomics will post -2.25 earnings per share for the current year.
A hedge fund recently bought a new stake in BioNano Genomics stock. Millennium Management LLC acquired a new stake in BioNano Genomics Inc (NASDAQ:BNGO) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 48,399 shares of the company’s stock, valued at approximately $254,000. Millennium Management LLC owned 0.48% of BioNano Genomics as of its most recent SEC filing. 9.81% of the stock is owned by institutional investors and hedge funds.
About BioNano Genomics
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Read More: Why are percentage decliners important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.